Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Two new option listings and four option delistings on November 1st » 08:30
11/01/19
11/01
08:30
11/01/19
08:30
CEMI

Chembio Diagnostics

$5.34 /

+0.04 (+0.75%)

, CUR

Neuralstem

$0.00 /

+ (+0.00%)

, HPJ

Highpower International

$4.80 /

-0.005 (-0.10%)

, UBNK

United Financial

$14.13 /

-0.39 (-2.69%)

New option listings for…

New option listings for November 1st include Chembio Diagnostics (CEMI) and Seneca Biopharma Inc (SNCA). Option delistings effective November 1st include Bristow Group Inc (BRSWQ), Neuralstem Inc (CUR), Highpower International Inc (HPJ), and United Financial Bancorp Inc (UBNK).

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$5.34 /

+0.04 (+0.75%)

07/09/19 Benchmark
Alibaba, Take-Two among Benchmark's Best Ideas for second half
06/17/19 Benchmark
Chembio Diagnostics price target lowered to $9 from $14 at Benchmark
01/04/19 Canaccord
Chembio Diagnostics initiated with a Buy at Canaccord
12/19/18
Chembio Diagnostics initiated with a Buy at Dougherty
CUR Neuralstem
$0.00 /

+ (+0.00%)

HPJ Highpower International
$4.80 /

-0.005 (-0.10%)

UBNK United Financial
$14.13 /

-0.39 (-2.69%)

07/17/19 Sandler O'Neill
United Financial upgraded to Buy from Hold at Sandler ONeill
04/17/19 Sandler O'Neill
United Financial downgraded to Hold from Buy at Sandler O'Neill
Hot Stocks
Seneca Biopharma, QYuns Therapeutics sign licensing agreement » 07:44
10/30/19
10/30
07:44
10/30/19
07:44
CUR

Neuralstem

$1.30 /

-0.04 (-2.99%)

Seneca Biopharma, (fka…

Seneca Biopharma, (fka Neuralstem) and Jiangsu QYuns Therapeutics Co., a China-based company focused on monoclonal antibody therapeutics, jointly announce that they have entered into a non-binding term sheet for the licensing of certain assets owned by QYuns. Subject to entering into definitive agreements and receiving necessary approvals, Seneca and QYuns will enter into a royalty- and milestone-free, perpetual, non-cancelable, exclusive worldwide, other than in Greater China (which includes Hong Kong, Macau and Taiwan and certain other Asian territories) license to develop and commercialize certain of QYuns' assets, including QX005N, targeting IL-4Ralpha, QX002N, targeting IL-17A, QX004N targeting IL-23A, and QX006N targeting IFNRalpha. As contemplated by the term sheet, Seneca will also gain access to future antibody assets developed by QYuns and the parties will collaborate on future pipeline expansion. Upon entering into the license, Seneca's lead asset will be SNC005 that targets IL-4Ralpha for the treatment of Asthma and Atopic Dermatitis. As consideration for the license, Seneca will issue QYuns a yet to be determined amount of common stock.

Hot Stocks
Neuralstem changes name to Seneca Biopharma » 09:11
10/28/19
10/28
09:11
10/28/19
09:11
CUR

Neuralstem

$1.32 /

+0.095 (+7.76%)

Neuralstem announces that…

Neuralstem announces that the company has changed its name to Seneca Biopharma. The company anticipates that its shares will begin trading on the NASDAQ Capital Market under the symbol SNCA on November 1 or shortly thereafter subject to the satisfaction of customary conditions of the exchange.

Hot Stocks
Neuralstem: Last subject enrolled in Phase 2 clinical trial of NSI-566 » 07:31
09/24/19
09/24
07:31
09/24/19
07:31
CUR

Neuralstem

$1.72 /

+0.06 (+3.61%)

Neuralstem announced…

Neuralstem announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke. NSI-566 is Neuralstem's lead stem cell therapy candidate, and has also been evaluated in clinical trials for patients with Amyotrophic Lateral Sclerosis and chronic spinal cord injury. The trial is being conducted at the BaYi Brain Hospita in Beijing, China under the direction of Professor Xu Ruxiang.

Hot Stocks
Neuralstem granted Nasdaq hearings panel request for continued listing » 07:38
08/07/19
08/07
07:38
08/07/19
07:38
CUR

Neuralstem

$2.17 /

+0.02 (+0.93%)

Neuralstem received a…

Neuralstem received a letter from Nasdaq informing the company that the Nasdaq Hearings Panel has granted the company's request for continued listing of the company's stock on Nasdaq. The Panel found that the company had (i) demonstrated compliance with the bid price requirement and (ii) addressed the Panel's questions regarding its stockholders' equity position and will continue its listing and that the matter is closed.

Hot Stocks
Fly Intel: Pre-market Movers » 09:03
07/26/19
07/26
09:03
07/26/19
09:03
GOOG

Alphabet

$1,134.34 /

-3.03 (-0.27%)

, GOOGL

Alphabet Class A

$1,136.69 /

-3.21 (-0.28%)

, AMZN

Amazon.com

$1,974.99 /

-25.51 (-1.28%)

, MCD

McDonald's

$214.54 /

+1.805 (+0.85%)

, SBUX

Starbucks

$91.07 /

+0.47 (+0.52%)

, TWTR

Twitter

$38.10 /

-0.64 (-1.65%)

, ABBV

AbbVie

$66.60 /

-0.87 (-1.29%)

, INTC

Intel

$52.16 /

-0.76 (-1.44%)

, VNE

Veoneer

$17.80 /

-0.1 (-0.56%)

, ITW

Illinois Tool Works

$158.67 /

-0.03 (-0.02%)

, CHTR

Charter

$405.67 /

-3.81 (-0.93%)

, LEA

Lear

$133.60 /

-3.3 (-2.41%)

, CUR

Neuralstem

$3.75 /

-1.58 (-29.64%)

, TYPE

Monotype Imaging

$16.16 /

-0.59 (-3.52%)

UP AFTER EARNINGS:…

UP AFTER EARNINGS: Alphabet (GOOGL), up 9%... McDonald's (MCD), up 2%... Twitter (TWTR), up 6%... AbbVie (ABBV), up 2%... Intel (INTC), up 4%... Veoneer (VNE), up 5%... Starbucks (SBUX), up 6%. ALSO HIGHER: Monotype Imaging (TYPE), up 23% after announcing that it has entered into an agreement to be acquired for $19.85 per share in cash, representing an aggregate equity value of approximately $825M. DOWN AFTER EARNINGS: Amazon (AMZN), down 1.5%... Illinois Tool Works (ITW), down 4%... Charter (CHTR), down 6%... Lear (LEA), down 4%. LOWER: Neuralstem (CUR), down 40% after its 2.778M share secondary offering priced at $2.70 per share.

ShowHide Related Items >><<
GOOG Alphabet
$1,134.34 /

-3.03 (-0.27%)

07/26/19 Jefferies
Alphabet price target raised to $1,500 from $1,450 at Jefferies
07/26/19 Morgan Stanley
Alphabet price target raised to $1,450 from $1,400 at Morgan Stanley
07/26/19 Credit Suisse
Alphabet price target raised to $1,500 from $1,400 at Credit Suisse
07/26/19 Oppenheimer
Alphabet price target raised to $1,370 from $1,342 at Oppenheimer
GOOGL Alphabet Class A
$1,136.69 /

-3.21 (-0.28%)

07/26/19 RBC Capital
Alphabet price target raised to $1,425 from $1,300 at RBC Capital
07/26/19 Wedbush
Alphabet price target raised to $1,500 from $1,350 at Wedbush
07/26/19 SunTrust
Alphabet price target raised to $1,400 from $1,325 at SunTrust
AMZN Amazon.com
$1,974.99 /

-25.51 (-1.28%)

07/26/19 Credit Suisse
Amazon.com price target lowered to $2,225 from $2,250 at Credit Suisse
07/26/19 Benchmark
Amazon should be bought on post-earnings pullback, says Benchmark
07/26/19 Canaccord
Amazon.com guidance reflects one-day delivery investment, says Canaccord
07/26/19 Stifel
Amazon one-day shipping expensive, but 'worth it,' says Stifel
MCD McDonald's
$214.54 /

+1.805 (+0.85%)

07/22/19 Longbow
McDonald's Q2 U.S. comps beat already reflected in sentiment, says Longbow
07/18/19 Cowen
McDonald's price target raised to $235 from $225 at Cowen
07/15/19 Wells Fargo
McDonald's price target raised to $235 from $218 at Wells Fargo
07/15/19 Piper Sandler
McDonald's price target raised to $226 from $209 at Piper Jaffray
SBUX Starbucks
$91.07 /

+0.47 (+0.52%)

07/26/19 Wedbush
Starbucks price target raised to $95 from $88 at Wedbush
07/26/19 Jefferies
Starbucks price target raised to $110 from $96 at Jefferies
07/26/19 Morgan Stanley
Starbucks price target raised to $88 from $81 at Morgan Stanley
07/26/19 BMO Capital
Starbucks price target raised to $84 from $77 at BMO Capital
TWTR Twitter
$38.10 /

-0.64 (-1.65%)

07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BMO Capital
Twitter's delayed cost activities to weigh on margins, says BMO Capital
07/22/19 Rosenblatt
Twitter initiated with a Neutral at Rosenblatt
07/17/19 KeyBanc
KeyBanc expects 'solid results' from Alphabet, Facebook
ABBV AbbVie
$66.60 /

-0.87 (-1.29%)

07/18/19 SVB Leerink
Allergan downgraded to Market Perform from Outperform at SVB Leerink
07/16/19
Allergan downgraded to Market Perform at Bernstein
07/10/19 Citi
AbbVie risk from Enbrel biosimilars likely manageable, says Citi
07/03/19 SunTrust
Allergan price target raised to $185 from $170 at SunTrust
INTC Intel
$52.16 /

-0.76 (-1.44%)

07/26/19 Roth Capital
Intel's 5G modem business divestiture 'encouraging,' says Roth Capital
07/26/19 Jefferies
Jefferies reiterates Underperform on Intel despite Q2 beat
07/26/19 Morgan Stanley
Intel server selling prices much stronger than expected, says Morgan Stanley
07/23/19 Roth Capital
Apple talks to buy Intel modem business reduces merchant competition, says Roth Capital
VNE Veoneer
$17.80 /

-0.1 (-0.56%)

07/17/19 Citi
Lear downgraded to Neutral from Buy at Citi
06/27/19 Credit Suisse
Veoneer initiated with a Neutral at Credit Suisse
05/06/19 BMO Capital
Veoneer price target lowered to $30 from $38 at BMO Capital
04/23/19
Fly Intel: Top five analyst upgrades
ITW Illinois Tool Works
$158.67 /

-0.03 (-0.02%)

07/10/19 Deutsche Bank
Deutsche says buy Stanley, sell Illinois Tool Works and Parker-Hannifin into Q2
06/26/19
Fly Intel: Top five analyst downgrades
06/26/19 Northcoast
Illinois Tool Works downgraded to Sell from Neutral at Northcoast
04/26/19
Fly Intel: Top five analyst upgrades
CHTR Charter
$405.67 /

-3.81 (-0.93%)

07/18/19 TD Securities
Charter downgraded to Hold from Buy at TD Securities
07/12/19 Pivotal Research
Charter price target raised to $500 from $425 at Pivotal Research
07/10/19 Nomura Instinet
Charter headwinds not reflected in valuation, says Nomura Instinet
06/14/19
Fly Intel: Top five analyst initiations
LEA Lear
$133.60 /

-3.3 (-2.41%)

07/17/19 Buckingham
Lear risk more balanced at current levels, says Buckingham
07/17/19
Lear downgraded to Sector Perform at RBC Capital after negative pre-announcement
07/17/19 Buckingham
Lear downgraded to Neutral from Buy at Buckingham
CUR Neuralstem
$3.75 /

-1.58 (-29.64%)

TYPE Monotype Imaging
$16.16 /

-0.59 (-3.52%)

06/21/19 JPMorgan
Monotype buyout in low $20's per share 'could make sense,' says JPMorgan
06/20/19 JPMorgan
Private equity buyer makes more sense for Monotype business, says JPMorgan
04/29/19 B. Riley FBR
Monotype Imaging downgraded to Neutral from Buy at B. Riley FBR
04/26/19 JPMorgan
JPMorgan trims Monotype Imaging target to $20 on 'disappointing' quarter
  • 26
    Jul
Syndicate
Neuralstem 2.778M share Secondary priced at $2.70 » 06:25
07/26/19
07/26
06:25
07/26/19
06:25
CUR

Neuralstem

$3.75 /

-1.58 (-29.64%)

H.C. Wainwright acted as…

H.C. Wainwright acted as sole book running manager for the offering.

Hot Stocks
Neuralstem announces 1-for-20 reverse stock split » 07:31
07/16/19
07/16
07:31
07/16/19
07:31
CUR

Neuralstem

$0.33 /

-0.0013 (-0.39%)

Neuralstem announced a…

Neuralstem announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective on Wednesday, July 17 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "CUR," at the market open on Thursday, July 18. The reverse stock split enables Neuralstem to regain compliance with the $1.00 minimum bid price condition of the NASDAQ Capital Market continued listing requirements.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.